Company news, research breakthroughs, and major announcements across industries.

Home/Health

Health

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

Merck_Logo_Horizontal_Teal-Grey_RGB.jpg
Merck_Logo_Horizontal_Teal-Grey_RGB.jpg

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invasive bladder cancer (MIBC). This approval, which also covers KEYTRUDA SC® [known as KEYTRUDA QLEXTM...

  • PublishedOctober 21, 2026 · 6:45 AM
  • LocationRAHWAY, N.J.
  • IndustryHealth
  • LanguageEN

Published by Business Wire. Read the original announcement for the full release.

Read the full announcement →

Latest from leading organizations

Explore recent announcements by organization